Tuesday, July 5, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home News

Bruker introduces fast BioAFM for automated mechanobiology

by Medical Finance
in News
NanoWizard V BioScience AFM
9
SHARES
102
VIEWS
Share on FacebookShare on Twitter

From Bruker JPKJan 12 2022Reviewed by Mychealla Rice

Bruker today announced the release of the JPK NanoWizard® V BioAFM, a novel system that marks a milestone in automation and ease of use for life science atomic force microscopy research.

NanoWizard V BioScience AFMNanoWizard V BioScience AFM. Image Credit: Bruker JPK

NanoWizard V is a very fast, automated BioAFM that can optionally be fully integrated with advanced optical microscopes. It enables rapid, quantitative mechanical measurements and the analysis of dynamics on samples ranging in size from sub-molecular to cells and tissues. The automated setup, alignment and re-adjustment of system parameters opens new possibilities for long-term, self-regulating experiments on mechanobiological dynamics.

“The system’s promised speed and resolution, ease of use, and up-to-millimeter-range capabilities make this a game changer for AFM investigations in nanomedicine and biomedical applications,” said Dr. David Martinez Martin, Senior Lecturer in Biomedical Engineering and Co-Chair of the Sensors and Diagnostics Cluster of the Nanohealth Network at the University of Sydney, Australia. The focus of Dr. Martinez Martin’s research is on the discovery of new biomarkers for health and disease, and cell physiology.

“We believe that the NanoWizard V is the most advanced BioAFM, and it combines three significant innovations in one system: rapid, quantitative mechanobiology measurements, fast scanning AFM, and automation that requires minimal user input,” added Dr. Heiko Haschke, Bruker’s Director of BioAFM.

Over the last decade, we have gathered a wealth of experience in quantitative nanomechanics using the PeakForce Tapping® and Quantitative Imaging (QI) modes. By uniting the best aspects of both in our new PeakForce-QITM mode, we empower novices and experts alike to perform high-resolution, quantitative mechanobiology BioAFM experiments. We expect this new system to significantly contribute to a more comprehensive understanding of dynamic cellular processes and correlated molecular mechanisms.”


Dr. Heiko Haschke, Director of BioAFM, Bruker

About the JPK NanoWizard V BioAFM

JPK NanoWizard V is the latest generation of Bruker’s industry-leading BioAFMs. It has been optimized for high spatio-temporal resolution with a large scan area, flexible experiment design, and outstanding integration with advanced optical microscope systems. Its PeakForce-QI mode enables fast and flexible quantitative nanomechanical measurements, significantly extending the capabilities of AFM in terms of speed and resolution. NanoWizard V features novel scanner and sensor technologies and state-of-the-art control software that encompasses an intuitive, workflow-based graphical user interface (GUI) to ensure true, easy-to-use AFM operation. The system comprises JPK’s signature high-speed, high-performance Vortis 2 control electronics, advanced digital control, and novel software concepts that enhance its multiparametric imaging capabilities and data processing routines. With motorized mapping and the DirectOverlay, DirectTiling, and ExperimentPlanner features, positions and measurements can be set up to run realign automatically, ensuring rapid sample observation and highest force sensitivity. Combined with the new automated hardware features and an extensive range of liquid cell and temperature control options, the JPK NanoWizard V enables users of all levels to focus entirely on their experiments and is, therefore, the ideal tool for multi-user environments or imaging facilities.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study identifies cellular receptors for alphaviruses shared across mosquitoes, humans, and animals

Gut virome may warn of a serious and often fatal disease in preterm infants

by Medical Finance
July 5, 2022
0

Immediately after birth, human infants begin to develop a complex, interwoven fabric of microbes in their gut. Known collectively as...

Scientists discover antibody that inhibits a broad range of sarbecoviruses

New approach successfully differentiates between antibodies against influenza and SARS-CoV-2

by Medical Finance
July 5, 2022
0

A new study shows that it is possible to use the genetic sequences of a person's antibodies to predict what...

Dog brains can detect speech and show different activity patterns to many languages

Researchers identify 16 distinct cell populations in a key brain region for substance use disorders

by Medical Finance
July 5, 2022
0

In a work of systematic biology that advances the field, University of Alabama at Birmingham researchers have identified 16 distinct...

First patient-derived stem cell model developed for studying oculocutaneous albinism

Researchers develop a live imaging system to observe collagen synthesis

by Medical Finance
July 5, 2022
0

"Proteins are the building blocks of our body": You have probably heard this phrase before. Proteins are essential to the...

MAIT cells exercise complex functions and may be targets for future immunotherapies and vaccines

Two strains of TB bacterium attack the lungs in completely different fashion, study finds

by Medical Finance
July 5, 2022
0

Two strains of the bacterium causing tuberculosis have only minor genetic differences but attack the lungs in completely different fashion,...

What are the benefits of Irish Life Sciences’ new 2.2 mL square well ‘V’ bottom plate?

FOODPathS project kicks off with seventeen key network organizations to coordinate EU policy priorities on food

by Medical Finance
July 5, 2022
0

To coordinate EU policy priorities on food, the EU-funded project FOODPathS kicked off with seventeen key network organizations last Friday....

Next Post
Malvern Panalytical expands pharmaceutical drug development solutions through the acquisition of Creoptix

Rensselaer scientists secure $3.5 million grant to develop a low-dose, oral COVID antiviral drug

Study: Comparison of Moderna Versus Pfizer-Biontech COVID-19 Vaccine Outcomes: A Target Trial Emulation Study In the U.S. Veterans Affairs Healthcare System. Image Credit: BaLL LunLa/Shutterstock

Comparing the Moderna and Pfizer-Biontech vaccines against SARS-CoV-2 infection

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Hospital 620x480
    How the test-to-treat pillar of the US covid strategy is failing patients
  • Pandemic 620x480
    Will pandemic-era flaws unleash improved health technology?
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply